Monitor whether the company successfully completes the $7.5 million Series C Preferred Stock financing, as this is critical for funding the planned Phase 2a clinical trial for Nu-3 gel. The direct listing itself provides no capital to the company. Investors should be aware of the substantial doubt about the company's ability to continue as a going concern and the potential for significant dilution from the Series C Preferred Stock conversion features.
Executive Summary
Lakewood-Amedex Biotherapeutics Inc. (LABT) is pursuing a direct listing on Nasdaq to register the resale of 4.69 million shares by existing shareholders, with no proceeds going to the company. The company is advancing its lead antimicrobial product, Nu-3 gel, for infected diabetic foot ulcers through clinical development, supported by a $7.5 million private placement in Series C Preferred Stock. The company has no revenue, reported net losses of $3.8 million in 2025, and faces substantial doubt about its ability to continue as a going concern.
Key Facts
- Company is conducting a direct listing on Nasdaq to register resale of 4,689,177 shares by existing shareholders; company will not receive any proceeds from the sale.
- Lead product candidate Nu-3 gel is in development for infected diabetic foot ulcers (iDFU), with plans for a Phase 2a clinical trial following receipt of $7.5 million in private financing.
- Company reported net losses of $3,847,637 in 2025 and $4,855,405 in 2024, with no revenue generated from product sales.
- Audited financial statements include an explanatory paragraph from the independent registered public accounting firm expressing substantial doubt about the company's ability to continue as a going concern.
- Company has agreed to issue $7.5 million of Series C Preferred Stock with conversion price reset provisions that could cause significant dilution to existing shareholders.
Financial Impact
The company will not receive proceeds from the resale of shares. The $7.5 million private placement will fund the Phase 2a clinical trial for Nu-3 gel. The company reported net losses of $3.8 million in 2025 and $4.8 million in 2024, with no revenue.
Risk Factors
- Substantial doubt about the company's ability to continue as a going concern
- No revenue and significant net losses
- Dependence on successful completion of private financing to fund clinical trials
- Potential for significant dilution from Series C Preferred Stock conversion features
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001213900-26-037938 |
| Document: ea024866812ex23-1.htm | 0001213900-26-037938 |
| Document: ea024866812ex23-2.htm | 0001213900-26-037938 |
| Document: 0001213900-26-037938-index-headers.html | 0001213900-26-037938 |
| Document: 0001213900-26-037938-index.html | 0001213900-26-037938 |
| Document: 0001213900-26-037938.txt | 0001213900-26-037938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | EFFECT | $1.67 $0.3100 | ▼ −81.44% | ▼ −79.96% | $0.2644 (−84.17%) |
Sep 18, 2026 5w ago | S-1 | $2.05 $0.5834 | ▲ +71.54% | ▲ +70.63% | $0.2644 (+87.10%) |
Jun 17, 2026 18w ago | 8-K | $0.6022 $0.1890 | ▼ −68.62% | ▼ −68.93% | $0.2644 (−56.09%) |
May 14, 2026 23w ago | EFFECT | $19.60 $7.70 | ▲ +60.71% | ▲ +59.86% | $0.2644 (+98.65%) |
May 6, 2026 24w ago | 3 | $33.00 $6.70 | ▼ −79.70% | ▼ −80.51% | $0.2644 (−99.20%) |
Apr 20, 2026 27w ago | EFFECT | — | awaiting T+20 | — | — |
Apr 1, 2026 29w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 11, 2026 32w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers